These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26274735)

  • 41. Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or with meropenem.
    Al Yami MS
    J Infect Public Health; 2017; 10(6):770-773. PubMed ID: 28209320
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New target concentrations for vancomycin in Hong Kong.
    You JH; Chow SS; Lui JW; Ip M
    Int J Antimicrob Agents; 2011 Jan; 37(1):83-4. PubMed ID: 21074378
    [No Abstract]   [Full Text] [Related]  

  • 43. Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function.
    Jeon N; Staley B; Klinker KP; Hincapie Castillo J; Winterstein AG
    Int J Antimicrob Agents; 2017 Jul; 50(1):63-67. PubMed ID: 28522340
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factors associated with acute kidney injury in children receiving vancomycin.
    Sinclair EA; Yenokyan G; McMunn A; Fadrowski JJ; Milstone AM; Lee CK
    Ann Pharmacother; 2014 Dec; 48(12):1555-62. PubMed ID: 25186624
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pediatric acute kidney injury induced by concomitant vancomycin and piperacillin-tazobactam.
    Abouelkheir M; Alsubaie S
    Pediatr Int; 2018 Feb; 60(2):136-141. PubMed ID: 29181890
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vancomycin-induced acute kidney injury after liver transplantation.
    Shi XP; Lao DH; Xu Q; Zhang M; Lu YH; Gong Y; Wang T
    Hepatobiliary Pancreat Dis Int; 2021 Aug; 20(4):403-406. PubMed ID: 33879407
    [No Abstract]   [Full Text] [Related]  

  • 47. Acute renal failure associated with vancomycin and β-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime.
    Moenster RP; Linneman TW; Finnegan PM; Hand S; Thomas Z; McDonald JR
    Clin Microbiol Infect; 2014 Jun; 20(6):O384-9. PubMed ID: 24118354
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acute kidney injury after myeloablative cord blood transplantation in adults: the efficacy of strict monitoring of vancomycin serum trough concentrations.
    Mae H; Ooi J; Takahashi S; Kato S; Kawakita T; Ebihara Y; Tsuji K; Nagamura F; Echizen H; Tojo A
    Transpl Infect Dis; 2013 Apr; 15(2):181-6. PubMed ID: 23279721
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project.
    Frazee E; Rule AD; Lieske JC; Kashani KB; Barreto JN; Virk A; Kuper PJ; Dierkhising RA; Leung N
    Am J Kidney Dis; 2017 May; 69(5):658-666. PubMed ID: 28131530
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Shen WC; Chiang YC; Chen HY; Chen TH; Yu FL; Tang CH; Sue YM
    Nephrology (Carlton); 2011 Nov; 16(8):697-703. PubMed ID: 21707841
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Achievement of Therapeutic Vancomycin Trough Serum Concentrations with Empiric Dosing in Neonatal Intensive Care Unit Patients.
    Ringenberg T; Robinson C; Meyers R; Degnan L; Shah P; Siu A; Sturgill M
    Pediatr Infect Dis J; 2015 Jul; 34(7):742-7. PubMed ID: 25629890
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship.
    Karino S; Kaye KS; Navalkele B; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Pogue JM
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3743-50. PubMed ID: 27067325
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis.
    Sinha Ray A; Haikal A; Hammoud KA; Yu ASL
    Clin J Am Soc Nephrol; 2016 Dec; 11(12):2132-2140. PubMed ID: 27895134
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of Rates of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin-Tazobactam Administered as an Extended versus Standard Infusion.
    Mousavi M; Zapolskaya T; Scipione MR; Louie E; Papadopoulos J; Dubrovskaya Y
    Pharmacotherapy; 2017 Mar; 37(3):379-385. PubMed ID: 28079263
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of a Pharmacist-Initiated Vancomycin Monitoring Program.
    Smith AP; Millares-Sipin CA; James M; Cohen H
    Consult Pharm; 2016 Sep; 31(9):505-10. PubMed ID: 27636875
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients.
    LeCleir LK; Pettit RS
    Pediatr Pulmonol; 2017 Aug; 52(8):1000-1005. PubMed ID: 28440913
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.
    Moise PA; Culshaw DL; Wong-Beringer A; Bensman J; Lamp KC; Smith WJ; Bauer K; Goff DA; Adamson R; Leuthner K; Virata MD; McKinnell JA; Chaudhry SB; Eskandarian R; Lodise T; Reyes K; Zervos MJ
    Clin Ther; 2016 Jan; 38(1):16-30. PubMed ID: 26585355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acute Kidney Injury in Patients Treated with IV Beta-Lactam/Beta-Lactamase Inhibitor Combinations.
    Rutter WC; Burgess DS
    Pharmacotherapy; 2017 May; 37(5):593-598. PubMed ID: 28247443
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized Controlled Trial to Determine the Efficacy of Early Switch From Vancomycin to Vancomycin Alternatives as a Strategy to Prevent Nephrotoxicity in Patients With Multiple Risk Factors for Adverse Renal Outcomes (STOP-NT).
    Carreno JJ; Kenney RM; Divine G; Vazquez JA; Davis SL
    Ann Pharmacother; 2017 Mar; 51(3):185-193. PubMed ID: 27838680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Supratherapeutic vancomycin levels after trauma predict acute kidney injury and mortality.
    Ley EJ; Liou DZ; Singer MB; Mirocha J; Srour M; Bukur M; Margulies DR; Salim A
    J Surg Res; 2013 Sep; 184(1):501-6. PubMed ID: 23731689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.